Cat. No. | Product name | CAS No. |
DC46393 |
JNJ-67856633
Featured
JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis. |
2230273-76-2 |
DC46394 |
MK-8262
Featured
MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research. |
1432054-03-9 |
DC46395 |
Z-FY-CHO
Featured
Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific cathepsin L (CTSL) inhibitor. |
167498-29-5 |
DC46399 |
ZN-c3
Featured
ZN-c3 is an orally active, highly potent and selective Wee1 inhibitor (IC50=3.9 nM). ZN-c3 can be used for the research of cancer. |
2376146-48-2 |
DC46405 |
ARD-2128
Featured
ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer. |
2222111-87-5 |
DC46408 |
Gly3-VC-PAB-MMAE
Featured
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). |
2684216-48-4 |
DC46417 |
TGFβRI-IN-3
Featured
TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology. |
2763602-67-9 |
DC46419 |
11R-VIVIT TFA
Featured
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy. |
|
DC46443 |
EML741
Featured
EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC50 of 23 nM, Kd of 1.13 μM for G9a. EML741 also inhibits DNMT1 (IC50, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated. |
2328074-38-8 |
DC46451 |
CC-90005
Featured
CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression. |
1799574-70-1 |
DC46455 |
SB 204741
Featured
SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1. |
152239-46-8 |
DC46471 |
RP101988
Featured
RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely. |
|
DC46491 |
BAY-8400
Featured
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 of 81 nM. BAY-8400 shows synergistic activity of DNA-PK inhibition when combined with DNA damage inducing cancer therapy, like targeted alpha radiation. |
|
DC46500 |
I-BET282E
Featured
I-BET282E is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282E shows pIC50s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD). |
2885162-99-0 |
DC46502 |
Brilacidin
Featured
Brilacidin (PMX 30063) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin is a defensin mimetic antibiotic compound. |
1224095-98-0 |
DC46524 |
HAIYPRH hydrochloride
Featured
HAIYPRH hydrochloride, a targeting ligand, can specially bind to transferrin receptor (TfR). HAIYPRH hydrochloride can mediate the transport of nanocarriers across the blood-brain barrier. |
268215-17-4 |
DC46532 |
MAGL-IN-4
Featured
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain. |
2135785-20-3 |
DC46535 |
THK-5475(THK 5475)
Featured
THK-5475(THK5475) is a precursor of THK-5470, a monoamine oxidase-B(MAO-B) imaging probe, could be used for neurological diseases study (from patent EP2019-846498). |
2410554-19-5 |
DC46604 |
CMD178
Featured
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 also is an inhibitor of STAT5 and inhibit Treg cell development. |
|
DC46625 |
HCV-IN-30
Featured
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively. |
1007882-23-6 |
DC46639 |
WH-4-025
Featured
WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2). |
1876463-35-2 |
DC46686 |
(R)-Pirtobrutinib
Featured
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. |
2101700-14-3 |